Anzeige
Mehr »
Montag, 06.10.2025 - Börsentäglich über 12.000 News
Das Paradox-Becken beweist seine Stärke - und American Critical Minerals sitzt direkt darauf
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41BQ3 | ISIN: US15117F8804 | Ticker-Symbol: NV40
NASDAQ
06.10.25 | 16:22
5,850 US-Dollar
+2,27 % +0,130
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CELLECTAR BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
CELLECTAR BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur CELLECTAR BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:16Cellectar Biosciences, Inc. - 8-K, Current Report5
13:06Cellectar Biosciences, Inc.: Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) ...97Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM Expected...
► Artikel lesen
24.09.Cellectar Biosciences, Inc.: Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)76
11.09.Cellectar Biosciences, Inc.: Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-22589
09.09.Cellectar Biosciences, Inc.: Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit49
14.08.Cellectar signals NDA submission for iopofosine I-131 in WM by early 2026 amid accelerated approval focus108
CELLECTAR BIOSCIENCES Aktie jetzt für 0€ handeln
14.08.Cellectar Biosciences GAAP EPS of -$3.39 beats by $0.3171
14.08.Cellectar Biosciences, Inc. - 8-K, Current Report21
14.08.Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update384Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and...
► Artikel lesen
14.08.Cellectar Biosciences, Inc. - 10-Q, Quarterly Report20
13.08.Cellectar Biosciences Q2 2025 Earnings Preview38
13.08.A Peek at Cellectar Biosciences' Future Earnings21
02.07.Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option157
01.07.Cellectar Biosciences prices $6 million public offering81
01.07.Cellectar Biosciences preist öffentliches Angebot von 6 Millionen US-Dollar220
01.07.Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering42
30.06.Cellectar Biosciences, Inc. - S-1/A, General form for registration of securities76
26.06.Cellectar Biosciences, Inc. - S-1, General form for registration of securities91
26.06.Cellectar und Nusano unterzeichnen mehrjährigen Radioisotopen-Liefervertrag119
26.06.Cellectar Biosciences, Inc.: Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement552Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative...
► Artikel lesen
Weiter >>
60 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,64